Early Effects of Intensive Lipid-Lowering Treatment on Plaque Characteristics Assessed by Virtual Histology Intravascular Ultrasound

다국어 초록 (Multilingual Abstract)

Purpose: The effects of short-term intensive lipid-lowering treatment on coronary plaque composition have not yet been sufficientlyevaluated. We investigated the influence of short-term intensive lipid-lowering treatment on quantitative and qualitative changes in plaque components of non-culprit lesions in patients with acute coronary syndrome.
Materials and Methods: This was a prospective, randomized, open-label, single-center trial. Seventy patients who underwent both baseline and three-month follow-up virtual histology intravascular ultrasound were randomly assigned to either an intensivelipid-lowering treatment group (ezetimibe/simvastatin 10/40 mg, n=34) or a control statin treatment group (pravastatin 20 mg, n=36). Using virtual histology intravascular ultrasound, plaque was characterized as fibrous, fibro-fatty, dense calcium, or necrotic core. Changes in plaque components during the three-month lipid-lowering treatment were compared between the two groups.
Results: Compared with the control statin treatment group, there was a significant reduction in low-density lipoprotein cholesterolin the intensive lipid-lowering treatment group (-20.4±17.1 mg/dL vs. -36.8±17.4 mg/dL, respectively; p<0.001). There were no statistically significant differences in baseline, three-month follow-up, or serial changes of gray-scale intravascular ultrasound parameters between the two groups. The absolute volume of fibro-fatty plaque was significantly reduced in the intensive lipid-loweringtreatment group compared with the control group (-1.5±3.4 mm3 vs. 0.8±4.7 mm3, respectively; p=0.024). A linear correlation was found between changes in low-density lipoprotein cholesterol levels and changes in the absolute volumes of fibro-fatty plaque (p<0.001, R2=0.209).
Conclusion: Modification of coronary plaque may be attainable after only three months of intensive lipid-lowering treatment.

참고문헌 (Reference)

1 Lee SW, "Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study" 76 : 2662-2672, 2012

2 Moreno PR, "The year in atherothrombosis" 44 : 2099-2110, 2004

3 Sacks FM, "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators" 335 : 1996

4 "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)" 344 : 1994

5 "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group" 339 : 1349-1357, 1998

6 Virmani R, "Pathology of the vulnerable plaque" 47 (47): C13-C18, 2006

7 Davis HR Jr, "Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cho-lesterol homeostasis" 279 : 33586-33592, 2004

8 Heart Protection Study Collaborative Group, "MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536high-risk individuals: a randomised placebo-controlled trial" 360 : 7-22, 2002

9 Puri R, "Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SAT-URN" 15 : 380-388, 2014

10 Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes" 350 : 1495-1504, 2004

11 LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease" 352 : 1425-1435, 2005

12 Sudhop T, "Inhibition of intestinal cholesterol absorption by ezetimibe in humans" 106 : 1943-1948, 2002

13 Rodriguez-Granillo GA, "In vivo intravascular ultrasoundderived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis" 46 : 2038-2042, 2005

14 서용성, "Impact of Statin Treatment on Strut Coverage after Drug-Eluting Stent Implantation" 연세대학교의과대학 56 (56): 45-52, 2015

15 Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes" 372 : 2387-2397, 2015

16 Ballantyne CM, "Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia" 93 : 1487-1494, 2004

17 Hong MK, "Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis" 2 : 679-688, 2009

18 Jukema JW, "Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)" 91 : 2528-2540, 1995

19 Schwartz GG, "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial" 285 : 1711-1718, 2001

20 Nissen SE, "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial" 295 : 1556-1565, 2006

21 "Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)" 344 : 633-638, 1994

22 Nissen SE, "Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial" 291 : 1071-1080, 2004

23 Nasu K, "Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound" 2 : 689-696, 2009

24 Okazaki S, "Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study" 110 : 1061-1068, 2004

25 Toi T, "Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin" 73 : 1466-1472, 2009

26 Ballantyne CM, "Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study" 149 : 464-473, 2005

27 Libby P, "Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization" 104 : 14S-18S, 1998

28 Nair A, "Coronary plaque classification with intravascular ultrasound radiofrequency data analysis" 106 : 2200-2206, 2002

29 Mintz GS, "American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents" 37 : 1478-1492, 2001

30 Pitt B, "Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators" 341 : 70-76, 1999